For years, the best cholesterol drug on the planet had one fatal flaw.
You had to inject yourself with it.
That just changed.
The USFDA has approved Lipfendra, Merck's new pill — and it's the world's first oral PCSK9 inhibitor.
Translation: the most powerful weapon against "bad" cholesterol just went from a needle… to a tablet.
Here's the number that should worry you.
185 million Indians have high LDL cholesterol.
That's 20.9% of the country.
And over 81% have some form of unhealthy blood fat, according to an ICMR-backed Lancet study.
LDL doesn't shout. It doesn't warn you.
It just quietly clogs your arteries for years.
Until the first symptom is a heart attack.
PCSK9 inhibitors aren't new. They're already considered one of the biggest cholesterol breakthroughs of the decade.
The catch? Every single one — evolocumab, alirocumab, inclisiran — needed an injection.
Enlicitide, the drug inside Lipfendra, changes exactly one thing:
💉 No more needles
💊 Just one pill, once a day
📉 Cuts LDL by roughly 56% in trials
🧬 Up to 58% in patients with the genetic condition familial hypercholesterolaemia
That's a 2,904-patient trial result nearly matching the injectables it's replacing.
Doctors are thrilled — cautiously.
"Statins are still our backbone, and they'll stay that way," one Mumbai cardiologist put it plainly.
Lipfendra is for people who still run high despite maxed-out statins, or can't tolerate them at all.
And the trial proving it actually prevents heart attacks — not just lowers numbers — is still ongoing.
Lowering your number and saving your life aren't automatically the same thing.
This pill isn't landing in Indian pharmacies tomorrow.
It still needs local regulatory approval.
And cost? Existing injectable versions already run past ₹1 lakh a year, with zero insurance cushion.
So the real question isn't whether Lipfendra works.
It's whether India can actually afford to let 185 million people use it.
That's all for now!
